2023 House Bill 5077

Health: pharmaceuticals; distribution of naloxone under the administration of opioid antagonist act to any individual; provide for.

A bill to amend 2019 PA 39, entitled “Administration of opioid antagonists act,” by amending the title and sections 103 and 107 (MCL 15.673 and 15.677), section 107 as amended by 2020 PA 321, and by adding section 106.

House Fiscal Agency Analysis

House Bill 5077 would amend the Administration of Opioid Antagonists Act to specify that an agency that purchased or otherwise obtained and possessed an opioid antagonist or an employee or agency of an agency who possessed an opioid antagonist distributed to that employee or agency could distribute that opioid antagonist directly or indirectly to any individual.

Introduced in the House

Oct. 3, 2023

Introduced by Rep. Curtis VanderWall (R-102) and 22 co-sponsors

Co-sponsored by Reps. Carrie Rheingans (D-47), David Prestin (R-108), Noah Arbit (D-20), Emily Dievendorf (D-77), Rachel Hood (D-81), Julie Brixie (D-73), Joey Andrews (D-38), John Fitzgerald (D-83), Lori Stone (D-13), Felicia Brabec (D-33), Jenn Hill (D-109), Kara Hope (D-74), Betsy Coffia (D-103), Erin Byrnes (D-15), Jasper Martus (D-69), Jim Haadsma (D-44), Jennifer Conlin (D-48), Ann Bollin (R-49), Regina Weiss (D-6), Christine Morse (D-40), Sharon MacDonell (D-56) and Abraham Aiyash (D-9)

Referred to the Committee on Health Policy

March 5, 2024

Reported without amendment

April 24, 2024

Passed in the House 96 to 11 (details)

Motion to give immediate effect by Rep. Abraham Aiyash (D-9)

The motion prevailed by voice vote

Received in the Senate

April 30, 2024

Referred to the Committee on Health Policy

Oct. 30, 2024

Reported without amendment

Oct. 31, 2024

Referred to the Committee of the Whole

Nov. 13, 2024

Reported without amendment